Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

Some cases expand on earlier initiatives, like the Valsartan cases. The theory against these was launched from the Zantac ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

There are plenty of fun facts about Italy. It's one of Europe's most visited countries. The history's long. The culture's rich. And the food's delectable. But what do you actually know? Here are our ...

The top headlines from today's far-reaching Budget at a glance, including National Insurance contribution changes ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK did reiterate its financial guidance for the year, however, helped by demand for its cancer and HIV drugs: at constant exchange rates it's still expecting revenue growth of 7% to 9%, core ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged.